

# IRMA IGF-I

Instruction for use in local language is available at [beckmancoulter.com/techdocs](http://beckmancoulter.com/techdocs).

## REVISION HISTORY

<b>Previous version:</b> IFU-A15729-05	<b>Current version:</b> IFU-A15729-06
<b>Standard curve</b> (Example of standard curve, do not use for calculation)	(Example of standard curve, do not use for calculation. Use the concentration of calibrators indicated on each vial label. The concentrations are lot specific, check carefully.)
—	Adding Ukrainian to the IFU.

**REF** A15729

## FOR PROFESSIONAL USE ONLY

## INTENDED PURPOSE

IRMA IGF-I is an in vitro diagnostic manual medical device intended to be used by healthcare professionals for the quantitative measurement of insulin-like growth factor I (IGF-I) in human serum and plasma. Measurement of insulin-like growth factor I is intended to be used in diagnosis and monitoring treatment of acromegaly and GH deficiency in general population [1, 2, 3, 4, 5, 6, 7].

## PRINCIPLE

The immunoradiometric assay of Insulin-like Growth Factor I (IGF-I) is a sandwich-type assay. Mouse monoclonal antibodies directed against two different epitopes of IGF-I and hence not competing are used. In order to release IGF-I from its binding proteins, a prior dissociation step is necessary. Samples or calibrators are incubated in tubes coated with the first monoclonal antibody in the presence of the second monoclonal antibody labeled with iodine 125. After incubation, the contents of tubes are rinsed so as to remove unbound <sup>125</sup>I-labeled antibody. The bound radioactivity is then determined in a gamma counter. The IGF-I concentrations in the samples are obtained by interpolation from the standard curve. The concentration of IGF-I in the samples is directly proportional to the radioactivity.

## WARNING AND PRECAUTIONS

### General remarks:

- The vials with calibrators and controls should be opened as shortly as possible to avoid excessive evaporation.
- Do not mix the reagents from kits of different lots.
- A standard curve must be established with each assay.
- It is recommended to perform the assay in duplicate.
- Each tube must be used only once.

### Basic rules of radiation safety

The purchase, possession, utilization, and transfer of radioactive material are subject to the regulations of the country of use. Adherence to the basic rules of radiation safety should provide adequate protection:

- No eating, drinking, smoking or application of cosmetics should be carried out in the presence of radioactive materials.
- No pipetting of radioactive solutions by mouth.
- Avoid all contact with radioactive materials by using gloves and laboratory overalls.
- All manipulation of radioactive substances should be done in an appropriate place, distant from corridors and other busy places.
- Radioactive materials should be stored in the container provided in a designated area.
- A record of receipt and storage of all radioactive products should be kept up to date.
- Laboratory equipment and glassware which are subject to contamination should be segregated to prevent cross-contamination of different radioisotopes.
- Each case of radioactive contamination or loss of radioactive material should be resolved according to established procedures.
- Radioactive waste should be handled according to the rules established in the country of use.

### Sodium azide

Some reagents contain sodium azide as a preservative. Sodium azide can react with lead, copper or brass to form explosive metal azides. Sodium azide disposal must be in accordance with appropriate local regulations.

### Materials of human origin

The materials of human origin, contained in this kit, were found negative for the presence of antibodies to HIV 1 and HIV 2, antibodies to HCV, as well as of Hepatitis B surface antigen (HBsAg). However, they should be handled as if capable of transmitting disease. No known test method can offer total assurance that no virus is present. Handle this kit with all necessary precautions.

All patient specimens should be handled as potentially infectious and waste should be discarded according to the country rules.

## GHS HAZARD CLASSIFICATION

Tracer

DANGER



H360  
P201  
P280

P308+P313

May damage fertility or the unborn child.  
Obtain special instructions before use.  
Wear protective gloves, protective clothing and eye/face protection.  
IF exposed or concerned: Get medical advice/attention.  
Sodium borate 1 - 3%

Wash Solution U (20X)

DANGER



H360  
P201  
P280

P308+P313

May damage fertility or the unborn child.  
Obtain special instructions before use.  
Wear protective gloves, protective clothing and eye/face protection.  
IF exposed or concerned: Get medical advice/attention.  
Boric Acid 0.1 - < 0.3%  
Sodium Borate Decahydrate 0.1 - < 0.3%

**SDS**

Safety Data Sheet is available at [beckmancoulter.com/techdocs](http://beckmancoulter.com/techdocs)

## SPECIMEN COLLECTION, PROCESSING, STORAGE AND DILUTION

- Serum or EDTA plasma are the recommended sample types.
- Allow serum samples to clot completely before centrifugation.
- Serum and plasma samples may be stored at 2-8°C, if the assay is to be performed within 24 hours. For longer storage keep frozen (at < -18°C, 1 year maximum), after aliquoting so as to avoid repeated freezing and thawing. Thawing of sample should be performed at room temperature.
- If samples have concentrations greater than the highest calibrator, they must be diluted in the dissociation buffer.

Serum and EDTA plasma values for 25 samples (serum values ranging from 54.13 to 237.6 ng/mL) were compared using the A15729 IRMA IGF-I. Results are as follows:

[EDTA-plasma] = 0.899 [serum] + 16.57

R = 0.9504

## MATERIALS PROVIDED

All reagents of the kit are stable until the expiry date indicated on the kit label, if stored at 2-8°C. Expiry dates printed on vial labels apply to the long-term storage of components by the manufacturer only, prior to assembly of the kit. Do not take into account.

Storage conditions for reagents after reconstitution or dilution are indicated in paragraph Procedure.

**Tubes: 2 x 50** (ready-to-use)

**<sup>125</sup>I-Tracer: one 33 mL vial** (ready-to-use)

The vial contains 370 kBq, at the date of manufacture, of <sup>125</sup>I-labeled immunoglobulins in liquid form, containing bovine serum albumin, sodium azide (<0.1%) and a dye. Avoid direct exposure to light.

**Calibrators: six vials** (lyophilized)

The calibrator vials contain from 0 to approximately 1,600 ng/mL of IGF-I in a buffer with bovine serum albumin and a preservative. The exact concentration is indicated on each vial label. The calibrators are traceable to the international reference standard, WHO 02/254.

**Control sample: one vial** (lyophilized)

The vial contains IGF-I lyophilized in a buffer with bovine serum albumin. The concentration range is indicated on a supplement. The control sample is traceable to the international reference standard, WHO 02/254.

**Dissociation buffer: two 25 mL vials** (ready-to-use)

The vial contains bovine serum albumin.

#### Wash solution U (20X): one 50 mL vial

Concentrated solution has to be diluted before use. It may be ordered separately, too (REF. A54825).

### MATERIALS REQUIRED, BUT NOT PROVIDED

In addition to standard laboratory equipment, the following items are required:

- Precision micropipette (50 µL).
- Semi-automatic pipette (300 µL, 1 mL and 2 mL).
- Vortex type mixer.
- Horizontal or orbital shaker.
- Aspiration system.
- Plastic tubes.
- Gamma counter set for <sup>125</sup>I.

### PROCEDURE

#### Preparation of reagents

Let all the reagents come to room temperature.

#### Reconstitution of calibrators and control sample

The content of the vials is reconstituted with the volume of distilled water indicated on the label. Wait for 30 min following reconstitution and mix gently to avoid foaming before dispensing. Store the reconstituted solutions at 2-8°C for one week or aliquoted at < -18°C for a longer time, until the expiry date of the kit.

#### Preparation of the wash solution

Pour the content of the vial into 950 mL of distilled water and homogenize. The diluted solution can be stored at 2-8°C until the expiry date of the kit.

#### Treatment of samples and control sample

Do not treat calibrators.

- To plastic tubes, add successively 50 µL of sample and 1 mL of dissociation buffer (these conditions allow to treat 50 samples; divide volumes by two to treat 100 samples, i.e. 25 µL of serum and 500 µL of buffer).
- Mix with a vortex-type shaker.
- Treated samples may be kept for 48h at 2-8°C; for longer storage keep at < -18°C (for up to 90 days).

#### Assay procedure

Step 1 Additions*	Step 2 Incubation	Step 3 Counting
To antibody coated tubes, add successively <b>in this order:</b> 300 µL of tracer, 50 µL of calibrator, control or sample. Vortex gently 1-2 seconds.	Incubate 60 minutes at 18-25°C with shaking (≥180 rpm).	Aspirate carefully the content of tubes (except the 2 tubes «total cpm»).
		Wash twice with 2 mL of wash solution.
		Count bound cpm (B) and total cpm (T) for 1 minute.

\* Add 300 µL of tracer to 2 additional tubes to obtain total cpm.

### RESULTS

Results are obtained from the calibrator curve by interpolation. The curve serves for the determination of analyte concentrations in samples measured at the same time as the calibrators.

#### Standard curve

The results in the quality control department were calculated using *spline* curve fit with log of determined radioactivity ( $cpm_{cal} - cpm_{cal0}$ ) or *B/T* after subtraction of Blank on the vertical axis and log of analyte concentration of the calibrators on the horizontal axis.

Other calculation methods may give slightly different results.

Total activity: 156,312 cpm				
Calibrators	IGF-I (ng/mL)	cpm (n=3)	B/T (%)	cpm <sub>cal</sub> - cpm <sub>cal0</sub>
0	0	295	-	-
1	25.0	1,057	0.49	762
2	81.0	4,256	2.53	3,961
3	280	18,919	11.9	18,624
4	543	42,561	27.0	42,266
5	1,600	71,994	45.9	71,699

(Example of standard curve, do not use for calculation. Use the concentration of calibrators indicated on each vial label. The concentrations are lot specific, check carefully.)

### Samples

For each sample, locate cpm (cpm<sub>sample</sub> - cpm<sub>cal0</sub>) or B/T **after subtraction of Blank** on the vertical axis and read off the corresponding analyte concentration on the horizontal axis.

## EXPECTED VALUES

We recommend each laboratory to establish its own reference values. The following values obtained from healthy subjects are indicative only.

### Adults

Age (years)	n	IGF-I (ng/mL)				
		Min.	5 <sup>th</sup> percentile	Median	95 <sup>th</sup> percentile	Max.
20-30	51	219	232	288	385	644
30-40	44	140	177	245	382	405
40-50	43	64	124	199	290	336
50-60	18	71	71	147	263	284
60-70	20	94	94	141	269	269
70-80	20	72	76	117	160	167

### Children

Stage of puberty		n	IGF-I (ng/mL)		
	(years)		Mean	Min.	Max.
P1	0-4	5	114	49	171
	>4	27	250	76	499
P2		6	303	247	396
P3		7	414	249	642
P4-P5		7	400	271	550

### Children constitutionally small

These children have a height that is lower by two standard deviations or more than average with GH concentration greater than 20 mIU/L after stimulation, and a regular rate of growth.

Stage of puberty		n	IGF-I (ng/mL)		
	(years)		Mean	Min.	Max.
P1	0-4	13	114	98	180
	5-7	25	115	98	156
	8-9	21	129	76	186
	10-11	24	151	76	234
	>12	27	198	131	278
		20	258	163	502
P2		14	351	185	617
P3		9	423	272	540
P4					

## QUALITY CONTROL

Good laboratory practices imply that control samples be used regularly to ensure the quality of the results obtained. These samples must be processed exactly in the same way as the assay samples, and it is recommended that their results be analyzed using appropriate statistical methods.

Failure to obtain the appropriate values for controls may indicate imprecise manipulations, improper sample handling or deterioration of reagents.

In case of packaging deterioration or if data obtained show some performance alteration, please contact your local distributor or use the following e-mail address: [imunochem@beckman.com](mailto:imunochem@beckman.com)

According to EU regulation 2017/746, any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of EU Member State in which the user and/or patient is located.

## PERFORMANCE CHARACTERISTICS

(For more details, see APPENDIX)

Representative data are provided for illustration only. Performance obtained in individual laboratories may vary.

### Sensitivity

**Analytical sensitivity:** 4.55 ng/mL

**Functional sensitivity:** 9.26 ng/mL

### Specificity

The antibodies used in the immunoassay are highly specific for IGF-I. Extremely low cross reactivities were obtained against several molecules (insulin, proinsulin, IGF II, GH).

#### **Precision**

##### **Intra-assay**

Serum samples were assayed 25 times in the same series. The coefficients of variation were found below or equal to 5.6%.

##### **Inter-assay**

Serum samples were assayed in duplicate in 10 different series. Coefficients of variation were found below or equal to 8.3%.

#### **Accuracy**

##### **Dilution test**

High-concentration serum samples were serially diluted with the dissociation buffer. The recovery percentages obtained were between 80.8% and 110%.

##### **Recovery test**

Low-concentration serum samples were spiked with known quantities of IGF-I. The recovery percentages obtained were between 86.4% and 110%.

**Measurement range** (from analytical sensitivity to the highest calibrator): 4.55 to approximately 1,600 ng/mL.

## **LIMITATIONS**

Failure to follow these instructions for use (IFU) may significantly affect results.

Results should be interpreted in the light of the total clinical presentation of the patient, including clinical history, data from additional tests and other appropriate information.

Do not use hemolyzed, lipemic or icteric samples. For more details, see Appendix, § Interference.

In immunoassays, the possibility exists for interference by heterophile antibodies in the patient sample. Patients who have been regularly exposed to animals or have received immunotherapy or diagnostic procedures utilizing immunoglobulins or immunoglobulin fragments may produce antibodies, e.g. HAMA, that interfere with immunoassays. Immunoassays may be also affected by presence of anti-avidin or anti-streptavidin antibodies, as well as by the presence of autoantibodies directed against the determined analyte. Such interfering antibodies may cause erroneous results. Carefully evaluate the results of patients suspected of having these antibodies [8, 9, 10].

**“Hook effect”:** no hook effect was observed until 7,000 ng/mL.

---

## APPENDIX

### PERFORMANCE CHARACTERISTICS

Representative data are provided for illustration only. Performance obtained in individual laboratories may vary.

#### Interference

Serum samples containing IGF-I concentrations (low and high) were spiked with multiple concentrations of the substances listed below and assayed using IRMA IGF-I KIT. Values were calculated as described in CLSI EP07, 3<sup>rd</sup> ed. [11]. Interference was determined by testing controls (no interfering substance added) and matched test samples (with interfering substance added). No interference (defined as a shift in dose > 15 %) was found for addition of interferent up to concentration stated in the table below.

Interferent	Test concentration
Biotin	2,090 ng/mL
Conjugated bilirubin	536.1 µg/mL
Hemoglobin	9,523 µg/mL
Triglycerides	18.86 mg/mL
Unconjugated bilirubin	469.1 µg/mL

In spite of hemoglobin, bilirubin (conjugated, unconjugated) and triglyceride interference data in the table, we advise to avoid using hemolyzed, lipemic or icteric samples.

#### Specificity

The specificity of the assay was determined by measuring the apparent IGF-I value given by high concentrations of related compounds in the absence (cross-reactivity) or presence of IGF-I.

#### Cross-reactivity

Related molecules	Concentration	IGF-I concentration measured	
	nM	ng/mL	nM
GH	40	0	0
Insulin	20	0	0
Proinsulin	40	0	0
IGF-II	650	0	0

Spiking	IGF-I concentration		IGF-I concentration	
	Expected		Measured	
	ng/mL	nM	ng/mL	nM
GH (40 nM) + IGF-I	270	35.3	274	35.6
Insulin (20 nM) + IGF-I	270	35.3	273	35.7
Proinsulin (40 nM) + IGF-I	270	35.3	266	34.8
IGF-II (670 nM) + IGF-I	294	35.3	278	36.1

#### Precision

##### Intra-assay

Serum	S1	S2	S3
Number of determinations	25	25	25
Mean value (ng/mL)	39.64	360.8	1,354
C.V., (%)	5.64	1.31	4.94

EDTA plasma	P1	P2	P3
Number of determinations	25	25	25
Mean value (ng/mL)	163.3	573.5	1,468
C.V., (%)	1.35	1.95	5.23

##### Inter-assay

Serum	S1	S2	S3
Number of determinations	10	10	10
Mean value (ng/mL)	38.02	94.56	930.9
C.V., (%)	8.29	3.66	4.79

EDTA plasma	P1	P2	P3
Number of determinations	10	10	10
Mean value (ng/mL)	59.74	87.91	956.1
C.V., (%)	5.98	5.90	4.66

**Accuracy****Dilution test**

Samples were diluted in dissociation buffer and assayed according to the assay procedure of the kit.

Serum	Dilution factor	Measured	Expected	Ratio (%) Measured/ Expected
		(ng/mL)		
S1	-	647.9	-	-
	1:2	337.6	324.0	104.2
	1:4	146.4	162.0	90.39
	1:8	70.64	80.99	87.22
	1:16	32.71	40.50	80.77
S2	-	709.4	-	-
	1:2	374.0	354.7	105.4
	1:4	170.4	177.3	96.06
	1:8	78.08	88.67	88.06
	1:16	39.33	44.33	88.71
S3	-	797.3	-	-
	1:2	437.6	398.7	109.8
	1:4	197.6	199.3	99.15
	1:8	89.35	99.66	89.65
	1:16	47.70	49.83	95.72
S4	-	767.2	-	-
	1:2	412.6	383.6	107.6
	1:4	189.0	191.8	98.55
	1:8	91.93	95.90	95.86
	1:16	40.63	47.95	84.74
S5	-	993.2	-	-
	1:2	502.3	496.6	101.1
	1:4	235.6	248.3	94.87
	1:8	110.3	124.1	88.86
	1:16	53.72	62.07	86.54
S6	-	983.7	-	-
	1:2	515.5	491.9	104.8
	1:4	251.8	245.9	102.4
	1:8	116.3	123.0	94.59
	1:16	55.70	61.48	90.59

EDTA plasma	Dilution factor	Measured	Expected	Ratio (%) Measured/ Expected
		(ng/mL)		
P1	-	718.1	-	-
	1:2	394.6	359.0	109.9
	1:4	192.6	179.5	107.3
	1:8	87.85	89.76	97.87
	1:16	40.14	44.88	89.44
P2	-	759.1	-	-
	1:2	406.1	379.5	107.0
	1:4	204.3	189.8	107.7
	1:8	94.03	94.89	99.10
	1:16	44.98	47.44	94.81
P3	-	877.0	-	-
	1:2	446.0	438.5	101.7
	1:4	216.5	219.3	98.72
	1:8	106.4	109.6	97.02
	1:16	49.44	54.81	90.20
P4	-	958.1	-	-
	1:2	442.5	479.1	92.37
	1:4	236.7	239.5	98.80
	1:8	111.6	119.8	93.19
	1:16	52.69	59.88	87.99
P5	-	921.6	-	-
	1:2	475.6	460.8	103.2
	1:4	229.5	230.4	99.61
	1:8	111.7	115.2	97.00
	1:16	54.46	57.60	94.55
P6	-	1,170	-	-
	1:2	577.6	585.0	98.73
	1:4	291.2	292.5	99.55
	1:8	136.5	146.2	93.34
	1:16	63.54	73.12	86.90

#### Recovery test

Samples were spiked with known quantities of IGF-I and assayed according to the assay procedure of the kit.

Serum	Endogen. conc.	Added conc.	Expected conc.	Measured conc.	Ratio (%) Measured/Expected
	(ng/mL)				
S1	158.8	111.8	254.5	259.2	102.0
	165.8	268.1	404.6	408.8	101.0
	162.6	525.9	607.7	639.3	105.2
S2	148.8	103.7	252.5	231.2	91.58
	155.0	235.2	390.2	350.0	89.70
	152.4	462.4	614.7	531.2	86.41
S3	191.5	127.8	319.3	351.3	110.0
	200.9	333.5	534.4	560.0	104.8
	197.0	588.8	785.8	809.6	103.0

EDTA plasma	Endogen. conc.	Added conc.	Expected conc.	Measured conc.	Ratio (%) Measured/Expected
	(ng/mL)				
P1	78.88	44.68	123.6	120.5	97.50
	75.21	127.8	203.0	171.5	84.47
	79.66	202.1	281.7	291.9	103.6
P2	117.9	49.03	166.9	149.6	89.62
	112.2	135.7	247.9	207.1	83.56
	119.2	218.6	337.8	339.5	100.5
P3	80.09	61.95	142.0	136.1	95.83
	75.35	166.5	241.9	212.9	88.00
	81.17	284.5	365.7	411.8	112.6



<sup>125</sup>I Characteristics

$T_{1/2} (^{125}\text{I}) = 1443 \text{ h} = 60.14 \text{ d}$

<sup>125</sup> I	E (MeV)	%
γ	0.035	6.5
K <sub>α</sub> X-ray	0.027	112.5
K <sub>β</sub> X-ray	0.031	25.4

Symbols Key
-------------

DANGER

Danger / Danger / Gefahr / Pericolo / Peligro / Perigo / Fara / Κίνδυνος / 危險 / Pavojus / Veszély! / Niebezpieczeństwo / Nebezpečí / Nebezpečnostvo / 위험 / Tehlike / Опасно! / Опасност / 危險

REF

Product Reference / Référéncé du produit / Produktreferenz / Riferimento prodotto / Número de referencia del producto / Referência do produto / Produktreferens / Κωδικός αναφοράς προϊόντος / 产品参考 / Gaminio nuoroda / Termékszám / Dane referencyjne produktu / Reference k produktu / Referenčné označenie výrobku / 제품 참조 자료 / Ūrūn Referansi / Ссылка на продукт / Референца за производ / 產品參考

IVD

In Vitro Diagnostic / Diagnostic in vitro / In-vitro-Diagnostikum / Diagnostica in vitro / Para diagnóstico in vitro / Diagnóstico in vitro / InVitro-diagnostik / Για διάγνωση in vitro / 体外诊断 / In vitro diagnostika / In vitro diagnosztikai felhasználásra / Diagnostyka in vitro / Diagnostika in vitro / 체외 진단 / In Vitro Diagnostik / Диагностика in vitro / За ин витро диагностика / 體外診斷

CONTENTS

Contents / Contenu / Inhalt / Contenuto / Contenido / Περιεχόμενο / 組成 / Rinkinio sudėtis / Tartalom / Zawartość / Obsah / Obsah / 내용물 / İçindekiler / Содержание / Съдържание / 目錄

Manufactured by / Fabriqué par / Hergestellt von / Prodotto da / Fabricado por / Tillverkas av / Κατασκευαστής / 制造商 / Gamintojas / Gyártó: / Producent / Výrobce / Výrobca / 제조

Üretici / Изготовлено / Произведено от / 製造商

Contains sufficient for <n> tests / Contenu suffisant pour "n" tests / Inhalt ausreichend für <n> Prüfungen / Contenuto sufficiente per "n" saggi / Contenido suficiente para <n> ensayos / Conteúdo suficiente para "n" ensaios / Räckert till "n" antal tester / Περιεχόμενο επαρκές για "n" εξετάσεις / 含量足够 <n> 次测试 / Turinio pakanka <n> tyrim / <n> teszthez elegendő mennyiséget tartalmaz / Zawartość wystarcza na <n> testów / Lze použít pro <n> testů / Obsah vystačí na <n> testov / <n> 테스트에 대해 충분한 양 포함 / <n> sayida test için yeterlidir / Содержит достаточно для количества тестов: <n> / Съдържа достатъчно за <n> теста / 内容物足夠執行 <n> 次測試

CE Mark / Marquage CE / CE-Kennzeichnung / Marchio CE / Marcado CE / Marcação CE / CE-märkning / Σήμανση CE / CE 标志 / CE ženklas / CE jelzés / Znak CE / Značka CE / Označenie CE / CE 표시 / CE İşareti / Маркировка CE / CE маркировка / CE 標識

Safety Data Sheet / Fiche technique santé-sécurité / Sicherheitsdatenblatt / Scheda dati di sicurezza / Hoja de datos de seguridad / Ficha de Dados de Segurança / Säkerhetsdatablad / Φύλλο Δεδομένων Ασφάλειας / 安全数据单 / Saugos duomenų lapas / Biztonsági adatlap / Karta Charakterystyki Bezpieczeństwa / Bezpečnostní list / Bezpečnostný list / 안전보건자료 / Güvenlik Bilgi Formu / Паспорт безопасности / Информационен Лист За Безопасност / 安全性資料表

Consult Instructions for Use / Consultez le mode d'emploi / Siehe Gebrauchsanweisung / Consultare le istruzioni per l'uso / Consulte las Instrucciones de uso / Instruções de utilização / Konsultera bruksanvisning / Συμβουλευτείτε τις οδηγίες χρήσης / 请参阅使用说明 / Skaitykite naudojimo instrukciją / Olvassa el a használati utasítást / Zapoznać się z instrukcją użycia / Postępujcie podle návodu k použití / Prečítajte si návod na použitie / 사용 안내 문의 / Kullanma Talimatına Başvurun / Обратитесь к инструкциям / Вижте Инструкциите за употреба / 請參閱使用說明

Temperature range(s) / Plage(s) de température / Temperaturbereich(e) / Intervallo/i di temperatura / Intervalo(s) de temperatura / Intervalo(s) de temperatura / Temperaturintervall / Εύρος(-η) θερμοκρασίας / 溫度范围 / Temperatūros diapazonas (-ai) / Hőmérséklet-tartomány(ok) / Zakres(y) temperatury / Rozsahy teplot / Rozsah(y) teploty / 온도 범위 / Sıcaklık aralıkları / Диапазон(-ы) температуры / Температурен(ни) диапазон(и) / 溫度範圍 請參閱使用說明

Caution / Précaution / Achtung / Attenzione / Precaución / Atenção / Försiktighet / Προσοχή / 注意事项 / Įspėjimas / Figyelem / Uwaga / Upozornění / Upozornenie / 주의 / Dikkat / Внимание / 注意

Expiration Date / Date D'expiration / Verfallsdatum, Verw. bis: / Data Di Scadenza / Fecha De Caducidad / Data de validade / Utgångsdatum / Ημερομηνία λήξης / 失效日期 / Galiojimo data / Lejárati idő / Data ważności / Datum expirace / Dátum expirácie / 만료 날짜 / Son Kullanma Tarihi / Срок годности / Срок на годност / 到期日

Lot Number / Numéro de lot / Chargennummer / Numero di lotto / Lote número / Número de lote / Satsnummer / Αριθ. παρτίδας / 批次号 / partijos numeris / Tételszám / Numer serii / Číslo šarže / 로트 번호 / Lot Numarası / Номер партии / Номер на партида / 批號

Date of Manufacture / Date de Fabrication / Herstellungsdatum / Data di Fabbricazione / Fecha de Fabricación / Data de Fabrico / Produktionsdatum / Ημερομηνία Παραγωγής / 生产日期 / Pagaminimo Data / Gyártás Dátuma / Data Produkcji / Datum Výroby / Dátum Výroby / 제조 일자 / Üretim Tarihi / Дата Производства / Дата на Производство / 製造日期



Biohazard / Risque biologique / Biogefährdung / Rischio biologico / Riesgo biológico / Risco biológico / Biologisk fara / Βιολογικός κίνδυνος / 生物危害 / Biologisk fara / Veszélyes biológiai anyag / Zagrożenie biologiczne / Biologické riziko / Biologické riziko / 생물학적 위험 / Biolojik tehlike / Биологическая опасность / Биологична опасност / 生物危害



Radioactive / Radioactif / Radioaktiv / Radioattivo / Radiactivo / Radioactivo / Radioaktivt / Ραδιενεργό / 放射性 / Radioaktyvioji medžiaga / Radioaktiv / Radioaktywny / Radioaktivní / Rádioaktívny / 방사성 / Radyoaktif / Радиоактивный / Радиоактивен / 具放射性



Tracer / Traceur / Tracer / Marcato / Trazador / Marcador / Tracer / Ανιχνευτής / 追踪剂 / Atsekamoji medžiaga / Nyomjelző / Znacznik / Radioindikátor / Indikátor (tracer) / 트레이서 / Tracer'lar / метка / Индикатор / 追蹤劑



Calibrator / Calibrateur / Kalibrator / Calibratore / Calibrador / Calibrador / Kalibrator / Βαθμονομητής / 校准品 / Kalibravimo medžiaga / Kalibrátor / Kalibrator / kalibrátor / Kalibrátor / 보정 물질 / Kalibrátor / Калибратор / Калибратор / 校正液



Control / Contrôle / Kontrolle / Controllo / Control / Controllo / Kontrolle / Μάρτυρας / 质控品 / Kontrolinė / Kontroll / Kontrola / Kontrola / Kontrola / 정도관리 / Kontrol / Контроль / Контролна / 質控品



Tubes / tubes / Röhrchen / provette / tubos / Tubos de amostra / Provrör / σωληνάρια / 试管 / Mégintuvéllai / Csövek / Probówki / Zkumavky / Skúmavky / 튜브 / Tüpler / пробирки / Епруветки / 試管



Instruction for Use / Mode d'emploi / Gebrauchsanweisung / Istruzioni per l'uso / Instrucciones de uso / Instruções de utilização / Bruksanvisning / Οδηγίες χρήσης / 使用说明 / Naudojimo instrukcija / Használati utasítás / Instrukcja użycia / Návod k použití / Návod na použitie / 사용 안내 / Kullanma Talimatı / Инструкции / Инструкции за употреба / 使用说明



Wash Solution Concentrate 20X / Solution de lavage concentrée 20X / Waschlösungskonzentrat 20X / Concentrato di soluzione di lavaggio 20X / Solución de lavado concentrada 20X / Concentrado de solução de lavagem 20X / Tvättlösningsskoncentrat 20X / Συμπυκνωμένο διάλυμα πλύσης 20X / 浓缩清洗液 20X / Plovimo tirpalo koncentratas 20X / 20X mosóoldat-koncentrátum / Koncentrat 20X roztworu płuczącego / Koncentrát mycího roztoku 20X / Koncentrát premývacieho roztoku 20X / 농축 세척액(20배) / Yıkama Çözeltisi Konsantresi 20X / Концентрат промывочного раствора 20X / Концентрат на разтвор за промиване 20X / 清洗溶液濃縮 20X



Buffer / Tampon / Puffer / Tampone / Tampón / Tampão / Buffert / Ρυθμιστικό Διάλυμα / 缓冲液 / Buferinis tirpalas / Puffer / Bufor / Pufr / Tlmiivý roztok / 완충액 / Tampon / Буфер / Буфер / 緩衝劑

## REFERENCES

1. Yuen K C J, Biller B M K, Radovick S, Carmichael J D, Jasim S, Pantalone K M, Hoffman A R. American association of clinical endocrinologists and American college of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. GHD Clinical Practice Guidelines, Endocr Pract. Oct 2019; 25(11), 1191-1232.
2. Katznelson L, Laws Jr E R, Melmed S, Molitch M E, Murad M H, Utz A, Wass J A H. Acromegaly: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. Nov 2014; 99(11), 3933-3951.
3. Molitch M E, Clemmons D R, Malozowski S, Merriam G R, Vance M L. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2011; 96(6), 1587-1609.
4. Ho K K Y. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. European Journal of Endocrinology. 2007; 157(6), 695-700.
5. Cohen P, Rogol A D, Deal C L, Saenger P, Reiter E O, Ross J L, Chernauek S D, Savage M O, Wit J M. Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. The Journal of Clinical Endocrinology & Metabolism. Nov 2008; 93(11), 4210-4217.
6. Collett-Solberg P F, Ambler G, Backeljauw P F, et al. Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective. Horm Res Paediatr. Sep 2019; 92(1), 1-14.
7. Grimberg A, DiVall S A, Polychronakos C, et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr. Nov 2016; 86(6), 361-397.
8. J Bjerner et al. - Immunometric Assay Interference - Incidence and Prevention; Clin Chem 48;4; 613-621, 2002
9. L J Kricka - Interferences in Immunoassay - Still a Threat; Clin Chem 46, No. 8, 2000
10. A. Dasgupta: Biotin and Other Interferences in Immunoassays – A Concise Guide. Elsevier, St. Louis, 2019
11. Approved Guideline - Interference Testing in Clinical Chemistry, EP07 3<sup>rd</sup> Edition. April 2018. Clinical and Laboratory Standards Institute.



IMMUNOTECH s.r.o., Radiova 1122/1, 102 00 Prague 10, Czech Republic  
www.beckmancoulter.com